Dr. Cella Discusses Axitinib and Sorafenib Axis Trial
Links shared publicly online about this topic.
- 212total visits
Dr. Cella Discusses Axitinib and Sorafenib Axis Trial
View full resource at onclive.com
Most Recently Shared on June 17, 2011 at 5:28 pm By:
OncLive TV: Dr. David Cella From @NUFeinbergMed Discusses Axitinib and Sorafenib Axis Trial http://t.co/iibTp4E
Symposier - Phase 3 Axitinib Data in patients with previously treated advanced renal cell carcinoma
symposier.com — “Uploaded and shared in Youtube by: OncUViewTV — Join study principal investigator Brian I. Rini, MD, for an in-depth discussion on Phase 3 trial results for axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) held at ASCO 2011 on June 6 as part of the Pfizer sponsored program. Dr. Rini presents the results from the first head-to-head study in previously treated advanced rCC.” View full resource at symposier.com
Most Recently Shared on June 20, 2011 at 6:12 pm By:
Symposier Nephrology Health Business and Nephrology
Axitinib vs Sorafenib as Second-Line therapy for Metatastic Renal Cell Carcinoma: Results of the Phase 3 AXIS Trial. http://bit.ly/mkP7YF
Advertisement
